BEIJING and SHANGHAI and BOSTON, April 30,
2024 /PRNewswire/ -- Jacobio Pharma (1167.HK)
announced that the data from the Phase II registrational study of
the KRAS G12C inhibitor glecirasib were offically reported at the
April ASCO Plenary Series, which was held online.
Prof. Yuankai Shi, chief
physician of Cancer Hospital Chinese Academy of Medical Sciences,
the lead principal investigator of this clinical trial, presented
the data in the form of an online oral presentation (Abstract
468214).
The efficacy data showed that among second-line non-small cell
lung cancer patients receiving monotherapy treatment, the confirmed
objective response rate (cORR) was 47.9% (56/117), including 4
patients achieved a complete response (CR) and 36 patients with
tumor reduction exceeding 50%. Disease control rate (DCR) was
86.3%.
The median progression-free survival (mPFS) was 8.2 months, and
median overall survival (mOS) was 13.6 months. The
median duration of response (mDoR) has not been
reached:6-month and 12-month DOR rates were 73.6% and 56.6%,
respectively.
Safety data showed that glecirasib has a manageable safety
profile. No grade 5 treatment related adverse event (TRAE) was
observed, and only 5.0% of patients discontinued the treatment due
to TRAEs. Gleciasib has a favorable gastrointestinal (GI)
profile compared to other KRAS G12C inhibitors.
"If glecirasib can match or even bypass current efficacy data
with an overall improved side effect profile, this agent would be
an attractive treatment option." commented Julia Rotow, MD, of the Dana-Farber Cancer
Institute, who critiqued the glecirasib findings. She said that the
unique toxicity profile of glecirasib may offer the potential for
combination with agents that cannot be readily combined with other
existing KRAS G12C inhibitors due to overlapping toxicities.
"The trend in the treatment of lung cancer is to reduce the use
of chemotherapy. Currently, for lung cancer patients harboring the
KRAS G12C mutation who fail first-line treatment, chemotherapy such
as docetaxel is the main second-line treatment in China. The ORR is 14%, mPFS is 3.0 months, and
OS is 9.1 months. Existing clinical data show that glecirasib is
more effective and safer than chemotherapy and is expected to bring
more treatment options to patients." Said Prof. Yuankai Shi.
About Glecirasib
Glecirasib is a KRAS G12C inhibitor developed by Jacobio. A
number of Phase I/II clinical trials of glecirasib are currently
ongoing in China, the United States and Europe for patients with advanced solid tumors
harboring KRAS G12C mutation. These include a pivotal clinical
trial in NSCLC in China; a
monotherapy study for STK11 co-mutated NSCLC in the front-line
setting, and combination therapy trials with SHP2 inhibitor JAB-3312 in NSCLC and with
Cetuximab in colorectal cancer. The pancreatic cancer indication
has obtained orphan drug designation in the United States and breakthrough therapy
designation in China.
About Jacobio
Jacobio Pharma (1167.HK) is committed to developing and
providing new and innovative products and solutions to improve
people's health. Our pipeline revolves around novel molecular
targets on six major signalling pathways: KRAS, immune checkpoints,
tumor metabolism, P53, RB and MYC. We aim for our key projects to
be among the top three in the world. Our vision is to become a
global leader recognized for our impact in drug R&D together
with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug
Discovery Platform (IADDP) and our iADC Platform.
Please visit www.jacobiopharma.com for more information
View original
content:https://www.prnewswire.com/news-releases/jacobio-pharma-announced-its-kras-g12c-inhibitor-reached-the-primary-endpoint-302132417.html
SOURCE Jacobio Pharma